<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genome Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genome Med</journal-id>
    <journal-title-group>
      <journal-title>Genome Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1756-994X</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6090738</article-id>
    <article-id pub-id-type="pmid">30071882</article-id>
    <article-id pub-id-type="publisher-id">571</article-id>
    <article-id pub-id-type="doi">10.1186/s13073-018-0571-0</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Exploring the OncoGenomic Landscape of cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Mateo</surname>
          <given-names>Lidia</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guitart-Pla</surname>
          <given-names>Oriol</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Duran-Frigola</surname>
          <given-names>Miquel</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3557-0236</contrib-id>
        <name>
          <surname>Aloy</surname>
          <given-names>Patrick</given-names>
        </name>
        <address>
          <email>patrick.aloy@irbbarcelona.org</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.473715.3</institution-id><institution>Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), </institution><institution>The Barcelona Institute of Science and Technology, </institution></institution-wrap>Barcelona, Catalonia Spain </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9601 989X</institution-id><institution-id institution-id-type="GRID">grid.425902.8</institution-id><institution>Institució Catalana de Recerca i Estudis Avançats (ICREA), </institution></institution-wrap>Barcelona, Catalonia Spain </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>3</day>
      <month>8</month>
      <year>2018</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>3</day>
      <month>8</month>
      <year>2018</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2018</year>
    </pub-date>
    <volume>10</volume>
    <elocation-id>61</elocation-id>
    <history>
      <date date-type="received">
        <day>6</day>
        <month>3</month>
        <year>2018</year>
      </date>
      <date date-type="accepted">
        <day>18</day>
        <month>7</month>
        <year>2018</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s). 2018</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">The widespread incorporation of next-generation sequencing into clinical oncology has yielded an unprecedented amount of molecular data from thousands of patients. A main current challenge is to find out reliable ways to extrapolate results from one group of patients to another and to bring rationale to individual cases in the light of what is known from the cohorts.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par2">We present <italic>OncoGenomic Landscapes</italic>, a framework to analyze and display thousands of cancer genomic profiles in a 2D space. Our tool allows users to rapidly assess the heterogeneity of large cohorts, enabling the comparison to other groups of patients, and using driver genes as landmarks to aid in the interpretation of the landscapes. In our web-server, we also offer the possibility of mapping new samples and cohorts onto 22 predefined landscapes related to cancer cell line panels, organoids, patient-derived xenografts, and clinical tumor samples.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par3">Contextualizing individual subjects in a more general landscape of human cancer is a valuable aid for basic researchers and clinical oncologists trying to identify treatment opportunities, maybe yet unapproved, for patients that ran out of standard therapeutic options. The web-server can be accessed at <ext-link ext-link-type="uri" xlink:href="https://oglandscapes.irbbarcelona.org">https://oglandscapes.irbbarcelona.org</ext-link>/.</p>
      </sec>
      <sec>
        <title>Electronic supplementary material</title>
        <p>The online version of this article (10.1186/s13073-018-0571-0) contains supplementary material, which is available to authorized users.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id>
            <institution>European Research Council</institution>
          </institution-wrap>
        </funding-source>
        <award-id>614944</award-id>
        <principal-award-recipient>
          <name>
            <surname>Aloy</surname>
            <given-names>Patrick</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011102</institution-id>
            <institution>Seventh Framework Programme</institution>
          </institution-wrap>
        </funding-source>
        <award-id>306240</award-id>
        <principal-award-recipient>
          <name>
            <surname>Aloy</surname>
            <given-names>Patrick</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007136</institution-id>
            <institution>Secretaría de Estado de Investigación, Desarrollo e Innovación</institution>
          </institution-wrap>
        </funding-source>
        <award-id>BIO2016-77038-R</award-id>
        <principal-award-recipient>
          <name>
            <surname>Aloy</surname>
            <given-names>Patrick</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2018</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par4">The widespread incorporation of next-generation sequencing into clinical oncology has yielded an unprecedented amount of molecular data from thousands of patients, holding promise for a healthcare revolution [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. One of the current challenges is to find out reliable ways to extrapolate results from one group of patients to another and to bring rationale to individual patients in the light of what is known from the cohorts. In this context, visualization tools that enable the exploration and analysis of large genomic datasets become essential for efficient interpretation and effective communication.</p>
    <p id="Par5">Conventional strategies often represent dysregulated genes in a cohort as a matrix, with samples as columns and genes as rows, sorted according to the frequency of the genomic alterations [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Although this representation is useful to identify the main driver genes and to find recurrent patterns, it often misses the capability of capturing the global structure of a cohort of patients or the comparison to other cohorts. Other approaches are more focused on exploiting population structure patterns based on genomic profile similarities computed considering the whole genome or transcriptome [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>]. The representations generated by these methods are difficult to interpret from a biological point of view since most of the genomic alterations considered are of unknown functional impact. Furthermore, with the exception of the recently presented TumorMap [<xref ref-type="bibr" rid="CR7">7</xref>], the available tools do not offer a means to locate individual patient data within the cohort as a whole. In this context, as a complementary approach, we have developed a visualization tool to allow the global characterization of cohorts, and that focuses on driver alterations with known functional impact on oncogenesis, yielding a global picture of a cohort that is biologically interpretable.</p>
  </sec>
  <sec id="Sec2">
    <title>Implementation</title>
    <sec id="Sec3">
      <title>Dataset summary</title>
      <p id="Par6">We collected 16,508 genomic profiles (coding somatic mutations and copy number variants) that are representatives of several cohorts of patients and cancer models (patient-derived xenografts, organoids, and cell lines). We considered the 92.15% of samples having a putatively oncogenic alteration in one or more genes covered by the IMPACT410 gene panel (see Table <xref rid="Tab1" ref-type="table">1</xref>). If solicited, future updates can easily incorporate larger patient cohorts, such as the complete TCGA [<xref ref-type="bibr" rid="CR10">10</xref>] and ICGC [<xref ref-type="bibr" rid="CR11">11</xref>] sets, and whole exome sequencing data, to complement the 410 genes included in the IMPACT panel [<xref ref-type="bibr" rid="CR12">12</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of sample size and provenance</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Biological source</th><th>No. of samples with SNV and CNV data</th><th>No. of samples with driver alterations in whole exome</th><th>No. of samples with driver alterations in IMPACT410</th></tr></thead><tbody><tr><td>TCGA [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>Patients</td><td>4058</td><td>3935</td><td>3850</td></tr><tr><td>MSK-IMPACT [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td>Patients</td><td>10,945</td><td>–</td><td>9869</td></tr><tr><td>Novartis PDXs [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>PDXs</td><td>375</td><td>375</td><td>375</td></tr><tr><td rowspan="3">OncoTrack [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td>Patients</td><td>117</td><td>109</td><td>109</td></tr><tr><td>PDXs</td><td>59</td><td>59</td><td>59</td></tr><tr><td>Organoids</td><td>46</td><td>46</td><td>46</td></tr><tr><td>GDSC Cell Lines [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td>Cell lines</td><td>908</td><td>904</td><td>904</td></tr><tr><td>TOTAL</td><td>–</td><td>16,508</td><td>5428</td><td>15,212</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec4">
      <title>Variant filtering</title>
      <p id="Par7">In order to filter out as many passenger alterations as possible, we applied a strict filtering pipeline described below, which was slightly tailored to each dataset:</p>
      <sec id="Sec5">
        <title>TCGA patients</title>
        <p id="Par8">We downloaded the <italic>Catalog of Driver Mutations – 2016.5</italic>, a curated dataset of known and predicted oncogenic coding mutations identified after analyzing 6792 exomes of a PanCancer cohort of 28 tumor types [<xref ref-type="bibr" rid="CR13">13</xref>]. We could complement this information with copy number variation data [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] for 4058 patients, representing 16 tumor types. In addition to the known and predicted oncogenic coding mutations, we also considered as oncogenic the deletion (GISTIC score ≤ − 2) of tumor suppressor genes and the amplification (GISTIC score ≥ 2) of oncogenes. The role of driver genes was established by inspecting the <italic>Catalog of Cancer</italic> Genes [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>MSKCC patients</title>
        <p id="Par9">We obtained both protein coding mutations (msk_impact_2017_mutations) and copy number variants (msk_impact_2017_cna) from the MSK_IMPACT Clinical Sequencing Cohort [<xref ref-type="bibr" rid="CR12">12</xref>] through cBioPortal [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Genes with a copy number alteration score ≤ − 2 or ≥ 2 were considered as putative deletions or amplifications, respectively.</p>
      </sec>
      <sec id="Sec7">
        <title>Novartis PDXs</title>
        <p id="Par10">We collected the 375 PDXs for which both mutations and copy number alterations were available [<xref ref-type="bibr" rid="CR17">17</xref>]. After analyzing the probability distribution of the estimated absolute copy number per gene, we considered absolute copy numbers below 1 or above 4 as gene deletions or amplifications, respectively. Using these criteria, we observed significant differences in gene expression between deleted tumor suppressors and amplified oncogenes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1A), confirming that those thresholds are biologically relevant.</p>
      </sec>
      <sec id="Sec8">
        <title>GDSC cell lines</title>
        <p id="Par11">We used gene level copy number data reported in the Genomics Drug Sensitivity in Cancer (GDSC) resource [<xref ref-type="bibr" rid="CR18">18</xref>], which is based on PICNIC analysis of Affymetrix SNP6.0 arrays. We considered genes with a minimum copy number of any genomic segment mapping to that gene below 1 or above 6 as gene deletions or amplifications, respectively. Using those thresholds, we observed significant differences in gene expression between deleted tumor suppressors and amplified oncogenes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1B), as described above for the analysis of copy number variants in PDXs.</p>
      </sec>
      <sec id="Sec9">
        <title>OncoTrack [<xref ref-type="bibr" rid="CR19">19</xref>]</title>
        <p id="Par12">We downloaded the genomic profiles of a biobank of 106 tumors, 35 organoids, and 59 xenografts. Copy number alterations were already annotated as “Amplification” or “Deletion.”</p>
        <p id="Par13">For MSK-IMPACT, Novartis PDXs, GDSC cell lines and OncoTrack datasets, protein-coding somatic mutations (following HGVS nomenclature recommendations), and copy number variants were classified into predicted passenger or known/predicted oncogenic alterations using the cancer genome interpreter resource [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
        <p id="Par14">After filtering out putative passenger alterations, we subsampled the dataset to consider only oncogenic alterations covered by the IMPACT410 gene panel [<xref ref-type="bibr" rid="CR20">20</xref>], which provided a much larger reference cohort (&gt; 10,000 patients MSKCC [<xref ref-type="bibr" rid="CR12">12</xref>]) while retaining enough signal to build meaningful OncoGenomic Landscapes.</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>2D projections</title>
      <p id="Par15">We built a Boolean matrix encoding the oncogenic alterations identified in each sample (in rows) and driver gene (in columns). We then calculated the Jaccard distance between all pairs of unique samples and used the resulting distance matrix as input for a metric multidimensional scaling (MDS), carried out using the <italic>scikit-learn</italic> implementation of MDS [<xref ref-type="bibr" rid="CR21">21</xref>] with default parameters (2 components, 4 SMACOF initializations, and a maximum of 300 iterations per run). As a result, we obtained (<italic>x</italic>, <italic>y</italic>) coordinates for each of the samples (i.e., a 2D projection). The corresponding level plots were generated by the 2D kernel density estimate function of the <italic>seaborn</italic> library, using 20 levels and a gray scale color-map as background. The PanCancer and more specific landscapes are the result of applying this procedure to the whole dataset and sample subsets, respectively.</p>
      <p id="Par16">To assess the significance of the distance metric and the dimensionality reduction strategy used to generate the landscapes, we examined whether the organization of samples in the PanCancer Landscape reflects the tissue-of-origin of the tumor. We observed a significant clustering of samples based on tissue-of-origin when examining both the Jaccard similarity coefficient in the multidimensional space and the Euclidean proximity in the MDS space. To evaluate the robustness of the current strategy, we also assessed the clustering of samples when using a Kernel PCA projection, an approach previously used in the field [<xref ref-type="bibr" rid="CR9">9</xref>]. We observed that the MDS projection yields greater spatial resolution compared to Kernel PCA and that the proximity in the MDS space has a stronger correlation with the proximity in the multidimensional space (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2).</p>
      <p id="Par17">When new samples are to be mapped onto a given landscape, we approximate their location by a nearest neighbor search in the original multidimensional space of genomic alterations (i.e., Jaccard distance). A new sample is assigned the (<italic>x</italic>, <italic>y</italic>) coordinate of its nearest neighbor, and the distance between them serves as a confidence score of the mapping. We found this simple strategy to be sufficient, as it yields an error comparable to the intrinsic one of SMACOF MDS (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3).</p>
    </sec>
    <sec id="Sec11">
      <title>Cohort overlays</title>
      <p id="Par18">In order to highlight the territory occupied by a subset of samples, we obtained the (<italic>x, y</italic>) coordinates of the selected samples in a given landscape and generated a 2D kernel density estimate with the <italic>kdeplot</italic> function using 20 levels, a transparent background, and contours colored using a color-map that represents probability density as heat.</p>
    </sec>
    <sec id="Sec12">
      <title>Driver landmark overlays</title>
      <p id="Par19">Similarly, to highlight the territory occupied by samples that have an oncogenic alteration in a given driver gene, we obtained the coordinates of those samples and generated a 2D kernel density estimate using 4 levels. We modified the resulting plots by removing the level with the lowest density and setting the same color and transparency to the rest of levels.</p>
    </sec>
    <sec id="Sec13">
      <title>Survival analysis</title>
      <p id="Par20">We used the median distance to the 22 nearest PDXs, which correspond to 5% of the 434 Novartis PDXs, as a measure of how far a patient is to the PDXs. Patients in the upper and lower quartiles of the median distance distribution were considered to be distal or proximal to PDXs, respectively. We compared the lifespans of patients that are proximal or distal to PDXs using the Kaplan-Meyer estimate of the survival function and performed a log-rank test to assess the statistical significance of the observed difference using the <italic>lifelines</italic> library. Additionally, we investigated the effect of distance to PDXs on survival using Cox’s proportional hazards regression model, adjusting for tumor type and patient provenance covariates.</p>
    </sec>
  </sec>
  <sec id="Sec14">
    <title>Results and discussion</title>
    <p id="Par21">We have developed a visualization tool that is mainly focused on the global characterization of cancer cohorts. Our computational pipeline mines and integrates genomic profiles from 13,827 cancer patients and 1385 cancer models (434 patient-derived xenografts, 46 organoids, and 905 cell lines), compares pairs of samples based on shared oncogenic alterations, and plots the results in a 2D space that we called OncoGenomic Landscape. We offer our tool as a web-based interface that enables the comparison of the main cohorts published to date, as well as the possibility of mapping new samples or cohorts on any of the available landscapes. Below, we describe some test cases to illustrate the utility of our tool, and we also provide a step-by-step tutorial on how to perform basic downstream analyses (available at <ext-link ext-link-type="uri" xlink:href="https://oglandscapes.irbbarcelona.org/tutorial">https://oglandscapes.irbbarcelona.org/tutorial</ext-link>).</p>
    <p id="Par22">Figure <xref rid="Fig1" ref-type="fig">1</xref> displays the distribution of samples across the PanCancer Landscape, including 15,212 genomic profiles from different tissues (see Table <xref rid="Tab1" ref-type="table">1</xref>). As expected, territories corresponding to recurrent drivers such as TP53 or KRAS are well populated (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Perhaps more interesting is the relatively large amount of patients that occupy a territory shared by TP53 and KRAS alterations, consistent with a significant co-occurrence observed in the MSK-IMPACT Clinical Sequencing Cohort [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], and suggesting a synergistic effect between these alterations. It is also apparent that samples with alterations in CDKN2A and CDKN2B occupy almost identical regions, which agrees with the finding that these two tumor suppressors are usually co-deleted as they are encoded next to each other in a very small locus [<xref ref-type="bibr" rid="CR22">22</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Visual display of the OncoGenomic Landscape of cancer. <bold>a</bold> PanCancer Landscape populated by 15,212 samples of 19 major tumor types of different biological origin (13,827 patients, 434 PDXs, 46 organoids, 905 cell lines). The territories occupied by samples that have at least one of the five most recurrent oncogenic alterations are shaded in different colors and serve as landmarks for molecular interpretation. <bold>b</bold> Distinct territories occupied by the nine most comprehensively characterized tumor types are depicted as transparent level plots overlaid on the PanCancer Landscape background. BRCA breast carcinoma, LUAD lung adenocarcinoma, COREAD colorectal adenocarcinoma, PRAD prostate cancer, GBM glioblastoma multiforme, RCCC renal clear cell carcinoma, CM cutaneous melanoma, OV ovarian cancer, and THCA thyroid cancer. <bold>c</bold> The OncoGenomic Landscape of breast invasive carcinoma (BRCA) patients is shown to illustrate how each of the 19 tumor type-specific landscapes is displayed in our web-server. Colors represent the territories occupied by samples having oncogenic alterations in five breast cancer specific landmark driver genes. <bold>d</bold> Boxplot showing the median distance of breast cancer samples to the 5% nearest neighbors in each comparison. The first two boxes compare the median distance of all breast cancer patients among themselves and to patients with other tumor types. The remaining pairs of boxes focus on patients that have an oncogenic alteration in each of the main five BRCA driver genes. Panels <bold>a</bold>, <bold>b</bold>, and <bold>c</bold> are screenshots directly obtained from the web-server. Panel <bold>d</bold> was generated after performing the statistical analysis outside of the app</p></caption><graphic xlink:href="13073_2018_571_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par23">Beyond key gene alterations, the PanCancer Landscape retains the tissue of origin of the tumors (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). We can observe how certain tumor types (e.g., glioblastoma or colorectal adenocarcinoma) often present a limited set of driver mutations and are thus restricted to very specific areas in the map, while other types (e.g., breast cancer or prostate adenocarcinoma) show a much more diverse pattern of oncogenic alterations and are widely spread. In both cases, it is possible to cluster cancer patients based on the tissue of origin of their tumor and to identify dominant groups representing each tumor type (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2), as previously suggested for the 12 major cancer types [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and, more recently, for the 33 cancer types that comprise the complete TCGA PanCancer Analysis [<xref ref-type="bibr" rid="CR6">6</xref>]. Moreover, we can zoom in on a region that is specific for a certain tumor type and capture patterns that might otherwise be hidden in the broader PanCancer Landscape (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). For instance, despite their considerable heterogeneity, we see that breast cancer samples are closer to each other than to other tumor types (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>). The observed proximity cannot be only attributed to the presence of common driver genes since we observe that tumor samples in different tissues sharing the most frequent driver alterations in breast cancer are significantly more distal. These results strongly suggest that our tumor type-specific territories capture complex mutational signatures that cannot be attained by analyzing driver genes individually.</p>
    <p id="Par24">The accurate comparison of patient or cancer model cohorts is fundamental to evaluate their molecular diversity and, more importantly, to assess whether information such as treatment benefits or prognostic factors learned from a reference group can be safely transferred to a new cohort. For instance, by comparing primary resections of treatment naïve tumors (3850 patients from The Cancer Genome Atlas (TCGA)) to 9869 clinically aggressive tumors from the Memorial Sloan Kettering Cancer Center (MSKCC), we can readily see than alterations in TP53 are much more common in the MSKCC cohort than in TCGA, as recently reported [<xref ref-type="bibr" rid="CR12">12</xref>], while BRAF alterations show the opposite trend (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). We believe that portrayals like this might also guide the design of clinical basket trials, where patients are selected based on their oncogenomic profiles regardless of their specific tumor type [<xref ref-type="bibr" rid="CR23">23</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Overlay of different OncoGenomic Landscapes. <bold>a</bold> The cohort of primary tumors from TCGA (<italic>n</italic> = 3850) is displayed as a transparent level plot overlaid on a largest cohort of clinically aggressive tumors from MSKCC (<italic>n</italic> = 9869), represented as a background landscape in gray scale. In a similar way, <bold>b</bold> pancreatic adenocarcinoma PDXs are overlaid on a cohort of PAAD patients (<italic>n</italic> = 377), <bold>c</bold> OncoTrack colorectal organoids (<italic>n</italic> = 46) are overlaid on colorectal adenocarcinoma patients (<italic>n</italic> = 1141), and <bold>d</bold> a panel of 905 cell lines is overlaid on 13,827 PanCancer patients. Panels <bold>b</bold> and <bold>d</bold> are screenshots directly obtained from the web-server. In panels <bold>a</bold> and <bold>d</bold>, we converted one of the landscapes into gray scale to enable a more visual comparison</p></caption><graphic xlink:href="13073_2018_571_Fig2_HTML" id="MO2"/></fig></p>
    <p id="Par25">We can also use OncoGenomic Landscapes to assess the molecular representativity of different model systems (cell lines, organoids, or patient-derived xenografts (PDXs)) with respect to a reference clinical cohort. For example, even though alterations in TP53, KRAS, and CDKN2A are the most prevalent in pancreatic ductal adenocarcinoma patients [<xref ref-type="bibr" rid="CR22">22</xref>], when we look at the tumors that successfully engrafted in mice (i.e., PDXs), we clearly see that CDKN2A-CDKN2B co-alterations are much more frequent in PDXs than it would be expected from clinical data (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>), supporting the idea that the simultaneous inactivation of CDKN2A and CDKN2B is required for the induction of pancreatic cancer in adult mice with overexpressed KRAS<sup>G12D</sup> and loss of TP53 [<xref ref-type="bibr" rid="CR22">22</xref>]. Conversely, we observe that the small collection of 69 OncoTrack colorectal organoids [<xref ref-type="bibr" rid="CR19">19</xref>] spans the molecular diversity seen in a much larger cohort of COREAD patients (188 from TCGA and 953 from MSKCC) (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). Finally, the overlay of 905 cancer cell lines [<xref ref-type="bibr" rid="CR18">18</xref>] on top of patient samples reveals a lack of cell models to study the effects of KRAS and BRAF mutations alone (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>).</p>
    <p id="Par26">Interestingly, we also find that distances in OncoGenomic Landscapes correlate with relevant clinical features. Mutations in the androgen receptor (AR) in prostate and in estrogen receptor (ESR1) in breast cancer are related to acquired resistance to hormonal therapies. The density of patients with mutations in those genes is notoriously higher in MSKCC than in TCGA, consistent with the known clinico-pathological differences of those two cohorts (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). We can also relate territories in the landscape to overall survival probabilities (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). It is well documented that during the establishment of PDXs, there is an engraftment bias towards more aggressive tumors [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Accordingly, we see that patients that are proximal to successfully engrafted tumors show a significantly worse prognosis than patients that are distal to PDXs (<italic>p</italic> value 9.74×10<sup>−36</sup>), and the trend remains significant (Cox regression <italic>p</italic> value 2.23 × 10<sup>−12</sup>) after adjusting for possible confounding factors such as tumor type and patient provenance (TCGA or MSKCC). This observation is in line with the recent finding that pancreatic ductal adenocarcinoma patients whose tumors did engraft in mice had significantly shorter recurrence-free and overall survivals than patients whose tumors failed to engraft [<xref ref-type="bibr" rid="CR24">24</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><p>Clinical relevance of OncoGenomic Landscapes. <bold>a</bold> Differences between TCGA and MSKCC cohorts related to resistance to endocrine therapy in PRAD and BRCA. The fraction of patients in each cohort presenting alterations in the androgen receptor (AR) and the estrogen receptor (ESR1) are shown in green and magenta, respectively. <bold>b</bold> Patient distance to PDXs correlates with overall survival probability. The territories occupied by PDXs are shown as a background landscape in gray scale whereas the location of patients that are proximal (red) or distal (blue) to PDXs are shown as transparent level plots. <bold>b</bold> Kaplan-Meyer analysis comparing the overall survival rate of patients that are proximal (red) or distal (blue) to PDXs. Panel <bold>a</bold> is composed of screenshots directly obtained from the webserver. Panel <bold>b</bold> was generated outside the app following the steps described in the tutorial available at <ext-link ext-link-type="uri" xlink:href="https://oglandscapes.irbbarcelona.org/tutorial">https://oglandscapes.irbbarcelona.org/tutorial</ext-link></p></caption><graphic xlink:href="13073_2018_571_Fig3_HTML" id="MO3"/></fig></p>
  </sec>
  <sec id="Sec15">
    <title>Conclusions</title>
    <p id="Par27">In summary, OncoGenomic Landscapes is a web-based visualization tool that organizes tumor samples, and other cancer models, in a 2D space, enabling the comparison of large cohorts and capturing their molecular heterogeneity. We offer the possibility of mapping new samples and cohorts onto a set of 22 predefined landscapes, providing an intuitive means to visualize user’s data and enrich it with knowledge transferred from the large corpus of cancer samples available today. Contextualizing individual patients in a more general landscape of human cancer is, we believe, a valuable aid for clinical oncologists trying to identify treatment opportunities, maybe in a compassionate use basis, for patients that ran out of standard therapeutic options.</p>
  </sec>
  <sec id="Sec16">
    <title>Availability and requirements</title>
    <p id="Par28"><italic>Project name:</italic> OncoGenomic Landscapes</p>
    <p id="Par29">
      <italic>Project home page:</italic>
      <ext-link ext-link-type="uri" xlink:href="https://oglandscapes.irbbarcelona.org">https://oglandscapes.irbbarcelona.org</ext-link>
    </p>
    <p id="Par30"><italic>Operating system(s)</italic><bold>:</bold> Platform independent</p>
    <p id="Par31"><italic>Programming language:</italic> Python, JavaScript <italic>(</italic>Node.js, D3.js and AngularJS)</p>
    <p id="Par32"><italic>Other requirements:</italic> Not applicable</p>
    <p id="Par33"><italic>License:</italic> Not applicable</p>
    <p id="Par34"><italic>Any restrictions to use by non-academics:</italic> Not applicable</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Additional file</title>
    <sec id="Sec17">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13073_2018_571_MOESM1_ESM.pdf">
            <label>Additional file 1:</label>
            <caption>
              <p>Contains the Supplementary Figures 1–3. (PDF 1055 kb)</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgements</title>
    <p>The authors would like to thank IRB Barcelona colleagues for providing feedback and testing the web-server.</p>
    <sec id="FPar1">
      <title>Consent of publication</title>
      <p id="Par35">Not applicable.</p>
    </sec>
    <sec id="FPar2">
      <title>Funding</title>
      <p id="Par36">L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2013-48222-R, BIO2016-77038-R), the European Commission (SyStemAge 306240), and the European Research Council (SysPharmAD 614944).</p>
    </sec>
    <sec id="FPar3">
      <title>Availability of data and materials</title>
      <p id="Par37">All the data used in our m/s can be found and downloaded from the accompanying web site <ext-link ext-link-type="uri" xlink:href="https://oglandscapes.irbbarcelona.org">https://oglandscapes.irbbarcelona.org</ext-link>.</p>
    </sec>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>LM, MDF, and PA conceived the study. LM, MDF, and OG designed the algorithm and implemented the software in python. OG developed the web-server. LM, MDF, and PA performed the analyses, interpreted the data, and wrote the manuscript. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="COI-statement">
    <p>Not applicable.</p>
    <p>The authors declare that they have no competing interests.</p>
    <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Biankin</surname>
            <given-names>AV</given-names>
          </name>
        </person-group>
        <article-title>The road to precision oncology</article-title>
        <source>Nat Genet</source>
        <year>2017</year>
        <volume>49</volume>
        <fpage>320</fpage>
        <lpage>321</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3796</pub-id>
        <?supplied-pmid 28232728?>
        <pub-id pub-id-type="pmid">28232728</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gerstung</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Papaemmanuil</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Martincorena</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Bullinger</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gaidzik</surname>
            <given-names>VI</given-names>
          </name>
          <name>
            <surname>Paschka</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Heuser</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thol</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bolli</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ganly</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Precision oncology for acute myeloid leukemia using a knowledge bank approach</article-title>
        <source>Nat Genet</source>
        <year>2017</year>
        <volume>49</volume>
        <fpage>332</fpage>
        <lpage>340</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3756</pub-id>
        <?supplied-pmid 28092685?>
        <pub-id pub-id-type="pmid">28092685</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kandoth</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>McMichael</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Wyczalkowski</surname>
            <given-names>MA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutational landscape and significance across 12 major cancer types</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>502</volume>
        <fpage>333</fpage>
        <lpage>339</lpage>
        <pub-id pub-id-type="doi">10.1038/nature12634</pub-id>
        <?supplied-pmid 24132290?>
        <pub-id pub-id-type="pmid">24132290</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hoadley</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Yau</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wolf</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Cherniack</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Tamborero</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ng</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Leiserson</surname>
            <given-names>MDM</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Uzunangelov</surname>
            <given-names>V</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin</article-title>
        <source>Cell</source>
        <year>2014</year>
        <volume>158</volume>
        <fpage>929</fpage>
        <lpage>944</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2014.06.049</pub-id>
        <?supplied-pmid 25109877?>
        <pub-id pub-id-type="pmid">25109877</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Consortium APG</collab>
        </person-group>
        <article-title>AACR project GENIE: powering precision medicine through an international consortium</article-title>
        <source>Cancer Discov</source>
        <year>2017</year>
        <volume>7</volume>
        <fpage>818</fpage>
        <lpage>831</lpage>
        <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id>
        <pub-id pub-id-type="pmid">28572459</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bailey</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Tokheim</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Porta-Pardo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sengupta</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bertrand</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Weerasinghe</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Colaprico</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wendl</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Reardon</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comprehensive characterization of cancer driver genes and mutations</article-title>
        <source>Cell</source>
        <year>2018</year>
        <volume>173</volume>
        <fpage>371</fpage>
        <lpage>385</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.060</pub-id>
        <?supplied-pmid 29625053?>
        <pub-id pub-id-type="pmid">29625053</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Newton</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Novak</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Swatloski</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>McColl</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Chopra</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Graim</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Weinstein</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Baertsch</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Salama</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Ellrott</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TumorMap: exploring the molecular similarities of cancer samples in an interactive portal</article-title>
        <source>Cancer Res</source>
        <year>2017</year>
        <volume>77</volume>
        <fpage>e111</fpage>
        <lpage>e114</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0580</pub-id>
        <?supplied-pmid 29092953?>
        <pub-id pub-id-type="pmid">29092953</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nicolau</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Carlsson</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2011</year>
        <volume>108</volume>
        <fpage>7265</fpage>
        <lpage>7270</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1102826108</pub-id>
        <?supplied-pmid 21482760?>
        <pub-id pub-id-type="pmid">21482760</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Prokopenko</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hecker</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Silverman</surname>
            <given-names>EK</given-names>
          </name>
          <name>
            <surname>Pagano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nothen</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Dina</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Fier</surname>
            <given-names>HL</given-names>
          </name>
        </person-group>
        <article-title>Utilizing the Jaccard index to reveal population stratification in sequencing data: a simulation study and an application to the 1000 Genomes Project</article-title>
        <source>Bioinformatics</source>
        <year>2016</year>
        <volume>32</volume>
        <fpage>1366</fpage>
        <lpage>1372</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btv752</pub-id>
        <?supplied-pmid 26722118?>
        <pub-id pub-id-type="pmid">26722118</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Cancer Genome Atlas Research N</collab>
          <name>
            <surname>Weinstein</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Collisson</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>GB</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Ozenberger</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Ellrott</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Shmulevich</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Stuart</surname>
            <given-names>JM</given-names>
          </name>
        </person-group>
        <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>
        <source>Nat Genet</source>
        <year>2013</year>
        <volume>45</volume>
        <fpage>1113</fpage>
        <lpage>1120</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>
        <pub-id pub-id-type="pmid">24071849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>International Cancer Genome C</collab>
          <name>
            <surname>Hudson</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Artez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Barker</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bernabe</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Bhan</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Calvo</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Eerola</surname>
            <given-names>I</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>International network of cancer genome projects</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>464</volume>
        <fpage>993</fpage>
        <lpage>998</lpage>
        <pub-id pub-id-type="doi">10.1038/nature08987</pub-id>
        <pub-id pub-id-type="pmid">20393554</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zehir</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Benayed</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Syed</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Middha</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Srinivasan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chakravarty</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Devlin</surname>
            <given-names>SM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>
        <source>Nat Med</source>
        <year>2017</year>
        <volume>23</volume>
        <fpage>703</fpage>
        <lpage>713</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.4333</pub-id>
        <?supplied-pmid 28481359?>
        <pub-id pub-id-type="pmid">28481359</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rubio-Perez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Tamborero</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Schroeder</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Antolin</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Deu-Pons</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Perez-Llamas</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mestres</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gonzalez-Perez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lopez-Bigas</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities</article-title>
        <source>Cancer Cell</source>
        <year>2015</year>
        <volume>27</volume>
        <fpage>382</fpage>
        <lpage>396</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2015.02.007</pub-id>
        <?supplied-pmid 25759023?>
        <pub-id pub-id-type="pmid">25759023</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cerami</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dogrusoz</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Sumer</surname>
            <given-names>SO</given-names>
          </name>
          <name>
            <surname>Aksoy</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Byrne</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Heuer</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>
        <source>Cancer Discov</source>
        <year>2012</year>
        <volume>2</volume>
        <fpage>401</fpage>
        <lpage>404</lpage>
        <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id>
        <?supplied-pmid 22588877?>
        <pub-id pub-id-type="pmid">22588877</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Aksoy</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Dogrusoz</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Dresdner</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sumer</surname>
            <given-names>SO</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sinha</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>
        <source>Sci Signal</source>
        <year>2013</year>
        <volume>6</volume>
        <fpage>pl1</fpage>
        <pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id>
        <?supplied-pmid 23550210?>
        <pub-id pub-id-type="pmid">23550210</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tamborero</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rubio-Perez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Deu-Pons</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Schroeder</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Vivancos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rovira</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tusquets</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Albanell</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rodon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tabernero</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations</article-title>
        <source>Genome Med</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>25</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-018-0531-8</pub-id>
        <?supplied-pmid 29592813?>
        <pub-id pub-id-type="pmid">29592813</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Korn</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Ferretti</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Monahan</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schnell</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response</article-title>
        <source>Nat Med</source>
        <year>2015</year>
        <volume>21</volume>
        <fpage>1318</fpage>
        <lpage>1325</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.3954</pub-id>
        <?supplied-pmid 26479923?>
        <pub-id pub-id-type="pmid">26479923</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Soares</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Greninger</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Edelman</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Lightfoot</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Forbes</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bindal</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Beare</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>IR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>D955</fpage>
        <lpage>D961</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id>
        <?supplied-pmid 23180760?>
        <pub-id pub-id-type="pmid">23180760</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schutte</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Risch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Abdavi-Azar</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Boehnke</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Schumacher</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Keil</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yildiriman</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Jandrasits</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Borodina</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Amstislavskiy</surname>
            <given-names>V</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>14262</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms14262</pub-id>
        <?supplied-pmid 28186126?>
        <pub-id pub-id-type="pmid">28186126</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Mitchell</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Zehir</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Benayed</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Syed</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chandramohan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>ZY</given-names>
          </name>
          <name>
            <surname>Won</surname>
            <given-names>HH</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>SN</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>
        <source>J Mol Diagn</source>
        <year>2015</year>
        <volume>17</volume>
        <fpage>251</fpage>
        <lpage>264</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jmoldx.2014.12.006</pub-id>
        <?supplied-pmid 25801821?>
        <pub-id pub-id-type="pmid">25801821</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <mixed-citation publication-type="other">Fabian Pedregosa GV, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V, Vanderplas J, Passos A, Cournapeau D, Brucher M, Perrot M, Duchesnay É. Scikit-learn: machine learning in python. <italic>JMLR</italic>. 2011;12:2825–30.</mixed-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Hao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>An</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lv</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Jiao</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A</article-title>
        <source>Oncogene</source>
        <year>2018</year>
        <volume>37</volume>
        <fpage>128</fpage>
        <lpage>138</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2017.316</pub-id>
        <?supplied-pmid 28892048?>
        <pub-id pub-id-type="pmid">28892048</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hyman</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Puzanov</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Subbiah</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Faris</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Chau</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Blay</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Wolf</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Raje</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Diamond</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Hollebecque</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations</article-title>
        <source>N Engl J Med</source>
        <year>2015</year>
        <volume>373</volume>
        <fpage>726</fpage>
        <lpage>736</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1502309</pub-id>
        <?supplied-pmid 26287849?>
        <pub-id pub-id-type="pmid">26287849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pergolini</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Morales-Oyarvide</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Mino-Kenudson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Honselmann</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Rosenbaum</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Nahar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kem</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ferrone</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>Lillemoe</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Bardeesy</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival</article-title>
        <source>PLoS One</source>
        <year>2017</year>
        <volume>12</volume>
        <fpage>e0182855</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0182855</pub-id>
        <?supplied-pmid 28854237?>
        <pub-id pub-id-type="pmid">28854237</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Whittle</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Lindeman</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Visvader</surname>
            <given-names>JE</given-names>
          </name>
        </person-group>
        <article-title>Patient-derived xenograft models of breast cancer and their predictive power</article-title>
        <source>Breast Cancer Res</source>
        <year>2015</year>
        <volume>17</volume>
        <fpage>17</fpage>
        <pub-id pub-id-type="doi">10.1186/s13058-015-0523-1</pub-id>
        <?supplied-pmid 25849559?>
        <pub-id pub-id-type="pmid">25849559</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
